These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia. Wang Y; Gali VL; Xu-Monette ZY; Sano D; Thomas SK; Weber DM; Zhu F; Fang X; Deng M; Zhang M; Hagemeister FB; Li Y; Orlowski RZ; Lee HC; Young KH Neoplasia; 2021 Apr; 23(4):361-374. PubMed ID: 33735664 [TBL] [Abstract][Full Text] [Related]
4. Waldenström macroglobulinemia: a review of pathogenesis, current treatment, and future prospects. Ghafoor B; Masthan SS; Hameed M; Akhtar HH; Khalid A; Ghafoor S; Allah HM; Arshad MM; Iqbal I; Iftikhar A; Husnain M; Anwer F Ann Hematol; 2024 Jun; 103(6):1859-1876. PubMed ID: 37414960 [TBL] [Abstract][Full Text] [Related]
5. Ibrutinib for the treatment of Waldenström macroglobulinemia. Chakraborty R; Kapoor P; Ansell SM; Gertz MA Expert Rev Hematol; 2015 Oct; 8(5):569-79. PubMed ID: 26138997 [TBL] [Abstract][Full Text] [Related]
12. Current treatment options for Waldenström macroglobulinemia. Vijay A; Gertz MA Clin Lymphoma Myeloma; 2008 Aug; 8(4):219-29. PubMed ID: 18765309 [TBL] [Abstract][Full Text] [Related]
13. Treatment of relapsed and refractory Waldenstrom Macroglobulinemia. Amaador K; Kersten MJ; Minnema MC; Vos JMI Leuk Lymphoma; 2023 Jan; 64(1):30-41. PubMed ID: 36282673 [TBL] [Abstract][Full Text] [Related]
14. What is new in the treatment of Waldenstrom macroglobulinemia? Castillo JJ; Treon SP Leukemia; 2019 Nov; 33(11):2555-2562. PubMed ID: 31591468 [TBL] [Abstract][Full Text] [Related]
15. CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review. Castillo JJ; Moreno DF; Arbelaez MI; Hunter ZR; Treon SP Expert Rev Hematol; 2019 Oct; 12(10):873-881. PubMed ID: 31343930 [No Abstract] [Full Text] [Related]
17. Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection. Kapoor P; Paludo J; Ansell SM Curr Treat Options Oncol; 2016 Mar; 17(3):16. PubMed ID: 26942591 [TBL] [Abstract][Full Text] [Related]
18. Waldenström macroglobulinemia: What a hematologist needs to know. Kapoor P; Paludo J; Vallumsetla N; Greipp PR Blood Rev; 2015 Sep; 29(5):301-19. PubMed ID: 25882617 [TBL] [Abstract][Full Text] [Related]
19. The Management of Relapsed or Refractory Waldenström's Macroglobulinemia. García-Sanz R; Tedeschi A Hematol Oncol Clin North Am; 2023 Aug; 37(4):727-749. PubMed ID: 37246089 [TBL] [Abstract][Full Text] [Related]
20. A safety profile of medications used to treat Waldenström's macroglobulinemia. García-Sanz R; Jiménez C; González De La Calle V; Sarasquete ME Expert Opin Drug Saf; 2018 Jun; 17(6):609-621. PubMed ID: 29768934 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]